ESALF:OTC-Eisai Co. Ltd (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 38.4

Change

0.00 (0.00)%

Market Cap

USD 11.39B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MKKGY Merck KGaA ADR

+1.45 (+4.19%)

USD 76.44B
MKGAF MERCK Kommanditgesellschaft au..

+0.77 (+0.43%)

USD 76.44B
HLNCF Haleon plc

-0.01 (-0.19%)

USD 47.58B
TKPHF Takeda Pharmaceutical Co. Ltd.

N/A

USD 47.42B
TEVJF Teva Pharmaceutical Industries..

N/A

USD 20.17B
SDZXF Sandoz Group AG

N/A

USD 18.03B
SDZNY Sandoz Group AG

+0.45 (+1.08%)

USD 17.63B
HNSPF Hansoh Pharmaceutical Group Co..

N/A

USD 13.26B
SWOBY Swedish Orphan Biovitrum AB (p..

N/A

USD 11.16B
IPSEY Ipsen SA ADR

N/A

USD 10.30B

ETFs Containing ESALF

1638:TSE 6.64 % 0.00 %

N/A

N/A
1621:TSE NEXT FUNDS TOPIX-17 Pharm.. 0.00 % 0.00 %

+455.00 (+0%)

USD 2.53B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.63% 47% F 32% F
Dividend Return 1.20% 10% F 18% F
Total Return -20.43% 49% F 31% F
Trailing 12 Months  
Capital Gain -30.26% 55% F 32% F
Dividend Return 2.14% 30% F 31% F
Total Return -28.12% 56% F 32% F
Trailing 5 Years  
Capital Gain -23.96% 82% B 50% F
Dividend Return 167.62% 91% A- 96% N/A
Total Return 143.66% 95% A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain -5.02% 50% F 29% F
Dividend Return 26.46% 71% C- 66% D+
Total Return 31.48% 84% B 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 59.23% 59% D- 46% F
Risk Adjusted Return 44.67% 94% A 81% B-
Market Capitalization 11.39B 97% N/A 92% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector